top of page

Sage Advises Cancer Prevention Pharmaceuticals on Merger with Panbela Therapeutics

Comments

Featured Posts

Sage Group Represents Solvotrin to License Their Novel ActiveIronTM Product Portfolio

Sage Group Represents Solvotrin to License Their Novel ActiveIronTM Product Portfolio

Sage Represents Mateon Therapeutics - Leadership in Novel Vascular Targeted Therapy

Sage Represents Mateon Therapeutics - Leadership in Novel Vascular Targeted Therapy

Recent Posts

Zumutor – Licensing Opportunity for Next Generation Tumor-Directed Immunotherapeutics Harnessing the Power of NK Cells

D-PLEX100 from Polypid for Prevention of Surgical Site Infections - Seeking a US Licensing Partner

Sage Group Advises Evecxia on Licensing of EVX-101, a Novel Treatment for Depression and OCD Using Serotonin Synthesis Amplification

The Sage Group: 30 Years of Successful Bioscience Transactions

Coagulant’s CT-001 - An Opportunity To License A Novel Factor VIIa with Orphan Drug Designation for the Treatment of Severe Postpartum Hemorrhage (sPPH)

Partnering/Licensing Opportunity for Tecarfarin, a Phase 3-Ready Oral Anticoagulant for Patients with Certain Orphan Diseases

Opportunity to License/Acquire CMX-2043 For Treatment of Traumatic Brain Injury

BullFrog AI Partners with the Sage Group to Explore JV Opportunities to Advance its Oncology Assets

The Sage Group advised Zhimeng Biopharma on a worldwide license to GSK of CB06-036, a TLR8 Agonist

AeroNeph Therapeutics Announces Search for Strategic Partners for Novel Drugs for Renal Disease

Archive

Search By Tags

Follow Us

bottom of page